I hope you will continue to be transparent, accessible, and willing to work with me and my colleagues.

I ask unanimous consent that the order for the quorum call be rescinded. The PRESIDING OFFICER. Without objection, it is so ordered. The Senator from Idaho.

I encourage you to recognize that Congress has the authority to make this determination.

I ask unanimous consent that the rollcall begin immediately. The PRESIDING OFFICER. Without objection. The question is, Will the Senate advise and consent to the Plumb nomination?

We appreciate this hearing's focus on examining the role that pharmacy benefit managers (PBMs) play in the American healthcare system.

In many ways, Medicare Part D reflects an unprecedented success story, coming in massively under budget, with low and stable monthly premiums--and with a generic drug dispensing rate of roughly 90 percent.

I have long championed efforts to improve prescription drug access and affordability for Americans, and I welcome the opportunity to engage in this vitally important bipartisan hearing.

We have to change that.

We need to identify avenues for lowering out-of-pocket costs, increasing competition, and promoting access to lifesaving innovation--and we need to do so in a fiscally responsible manner.

When we talk about the need for greater transparency in the drug supply chain, that term can and should mean a few different things.

Today, I am introducing legislation called the Lower Drug Costs for Families Act, and what it will do is penalize pharmaceutical companies for increasing the price of their drugs faster than the rate of inflation.

That said, much has changed in the past 2 decades, and we have an obligation both to build on the aspects of Part D that work well and to address access and affordability gaps where we find them.

Some of the most lifesaving medications remain out of reach for far too many working families and seniors.

We have got to figure out how to strengthen Medicare.

I have long championed efforts to improve prescription drug access and affordability for all Americans.

Some of the most lifesaving medications remain out of reach for far too many working families and seniors.

Obviously, transparency is key.

In many ways, Medicare Part D reflects an unprecedented success story, coming in massively under budget, with low and stable monthly premiums--and with a generic drug dispensing rate of roughly 90 percent.

We have got to figure out how to strengthen Medicare.

I have long championed efforts to improve prescription drug access and affordability for all Americans.

We need to identify avenues for lowering out-of-pocket costs, increasing competition, and promoting access to lifesaving innovation--and we need to do so in a fiscally responsible manner.

Today, I am introducing legislation called the Lower Drug Costs for Families Act, and what it will do is penalize pharmaceutical companies for increasing the price of their drugs faster than the rate of inflation.

Obviously, transparency is key.

I have long championed efforts to improve prescription drug access and affordability for Americans, and I welcome the opportunity to engage in this vitally important bipartisan hearing.

That said, much has changed in the past 2 decades, and we have an obligation both to build on the aspects of Part D that work well and to address access and affordability gaps where we find them.